Cancer Center at Illinois
Merit-Based Research Awards & Services
Merit-Based Research Awards & Services
The Cancer Center at Illinois (CCIL) supports the most innovative ideas from Illinois faculty. CCIL grant programs spark transdisciplinary collaborations that develop projects from early ideas to a competitive external funding proposal. These funding opportunities foster collaborations that reach across the engineering and biology continuum. Each application is reviewed and discussed by a panel of reviewers, following a process similar to that used by NIH.
Internal Funding Initiatives
Seed Grants
Seed grants solicit interdisciplinary research proposals to initiate or enhance collaborations among CCIL members and Illinois faculty.
Bridge Grants
Bridge grants provide assistance to cancer-focused research grant proposals that are at the R01 or multi-project level mechanisms.
Planning Grants
Planning grants bring together faculty from multiple disciplines to develop collaborative ideas and programs or collect preliminary data over one year.
Collaborative Funding Initiatives
BEAT Cancer
The Breakthrough Engineering and Advanced Treatment of (BEAT) Cancer Research Initiative is a collaborative effort with the OSF HealthCare Cancer Institute to drive innovative cancer treatment and care solutions by leveraging cutting-edge technologies within the scientific and medical communities.
Services
The Cancer Center at Illinois offers funding support to help members access specialized research services and technologies that advance cancer research. These services provide financial support for shared resources, compound screening, and preclinical testing. Each service has specific eligibility and funding limits.
Tumor Engineering and Phenotyping (TEP) Shared Resource Support
This program provides funding support for CCIL members to access services offered through the Tumor Engineering and Phenotyping Shared Resource. The facility provides specialized technologies, cancer models, and expertise to support cancer research.
PRISM Compound Evaluation Support
This program provides reimbursement support for compound testing through the PRISM evaluation service from Broad Institute. This service tests anticancer compounds against ~1,000 cancer cell lines in culture, reporting back IC50 values for each of the cell lines. In addition, users receive detailed bioinformatic information, where cell line sensitivity is correlated to expression and mutational patterns; this information can help determine the mode-of-action and translational potential of the compound.
See individual service descriptions at the link below for service details and submission information.
Research Funding Mailing List
The Office of the Vice Chancellor for Research and Innovation shares additional funding opportunities through a weekly funding email. Subscribe to the list below.